Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementationby Stanton L. Gerson
The Second Edition of Gene Therapy of Cancer provides crucial updates on the basic science and ongoing research in this field, examining the state of the art technology in gene therapy and its therapeutic applications to the treatment of cancer. The clinical chapters are improved to include new areas of research and more successful trials. Chapters emphasize the scientific basis of gene therapy using immune, oncogene, antisense, pro-drug activating, and drug resistance gene targets, while other chapters discuss therapeutic approaches and clinical applications. This book is a valuable reference for anyone needing to stay abreast of the latest advances in gene therapy treatment for cancer.
* Provides in-depth description of targeted systems and treatment strategies
* Explains the underlying cancer biology necessary for understanding a given therapeutic approach
* Extensively covers immune therapeutics of vaccines, cytokines, and peptide-induced responses
* Presents translational focus with emphasis on requirements for clinical implementation
* Incorporates detailed illustrations of vectors and therapeutic approaches ideal for classroom presentations and general reference
Description: This is a textbook of the gene therapy of cancer.
Purpose: The purpose is to provide a comprehensive review of the basis and approaches involved in the gene therapy of cancer. The authors are successful in devising an easily read textbook for gene therapy that provides a basic understanding of retroviral vectors and their clinical application. It is relatively comprehensive in its appropriate initial orientation to gene therapy, without the in-depth biology found in some molecular biology textbooks.
Audience: The audience is physicians, students, nurses, and researchers interested in gene therapy and its clinical application in cancers. The book is written by credible investigators in the field and it fulfills its objectives.
Features: This book has multiple black-and-white and color illustrations and figures to help clarify points within the text. The references to each chapter are generally extensive in providing further resource materials. Although the book lacks the in-depth character of a molecular biology textbook, it provides an excellent orientation and thought-provoking analysis of the field of gene therapy as it pertains to cancer.
Assessment: This is a well-written book that is well worth the time of investigators interested in understanding the field of gene therapy in relation to medical oncology.
"...offers a comprehensive review of the rapidly evolving field of cancer gene therapy for basic, translational, and clinical scientists. The editors have assembled a distinguished group of academic contributors... Their insights into the progress of cancer gene therapy and the challenges ahead are thoughtful and provocative." - GYNECOLOGIC ONCOLOGY
- Elsevier Science
- Publication date:
- Sold by:
- Barnes & Noble
- NOOK Book
- File size:
- 12 MB
- This product may take a few minutes to download.
Read an Excerpt
An invaluable reference to this rapidly expanding field
Meet the Author
Stanton L Gerson is Director of the Case Comprehensive Cancer Center&the National Center for Regenerative Medicine at Case Western Reserve University and Director of University Hospitals Seidman Cancer Center in Cleveland. Dr. Gerson studies DNA repair, stem cells and cancer therapy. He showed that over-expression of the MGMT DNA repair gene could prevent cancer and that a mutant form of MGMT protects hematopoietic stem cells from chemotherapy using lentiviral gene therapy. He has interrogated MGMT, MMR and BER DNA repair pathways as targets for cancer therapy, and proposed that methoxyamine would block base excision repair used in combination with chemotherapy. Dr. Gerson also directed the initial use of mesenchymal stem cells (MSCs) in bone marrow transplantation&in gene therapy.
Edmund C. Lattime is Professor of Surgery at the Robert Wood Johnson Medical School and Deputy Director, The Cancer Institute of New Jersey. Dr. Lattime studies tumor immunology and immunotherapy focusing on the tumor-host interaction and the tumor microenvironment. While faculty at Sloan Kettering and then Thomas Jefferson University, his translational studies led to the development and Phase I testing of a novel Vaccinia-GMCSF construct designed to enhance the development of antitumor immunity via infection/transfection of the tumor microenvironment. Based on his mechanistic studies of immune escape mechanisms, his group recently developed and is testing a poxvirus-based immunization strategy, which uses antigen encoding poxvirus delivered to the tumor microenvironment, in patients with locally-advanced pancreatic cancer.
Stanton L. Gerson received his M.D. at Harvard Medical School. He was a Resident in Medicine at the Hospital of the University of Pennsylvania, where he became a Fellow in Hematology-Oncology in 1980. He is an Edward Mallinckrodt Jr. Foundation Scholar, and is currently Chief, Division of Hematology/Oncology at Case Western Reserve Univeristy, where he has served since 1983. Dr. Gerson is a member of several major professional and scientific societies and is a principal investigator of funded grants for several philanthropic organizations. He is author or a contributor to over 200 research papers, abstracts, theses and book chapters. Since 1987, Dr. Gerson has been invited to be a guest lecturer at over 40 national and international conferences.
and post it to your social network
Most Helpful Customer Reviews
See all customer reviews >